Evidence map›Paper›PMID 36703579›Full record

SynthesisCurrent neuropharmacology2023

Pharmacological Treatments for Congenital Myasthenic Syndromes Caused by

Shuai Shao, Guanzhong Shi, Fang-Fang Bi, Kun Huang

Abstract readReviewMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Current neuropharmacology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Efficacy of ephedrine treatment in COLQ-related Congenital Myasthenic Syndrome (CMS): longitudinal quantitative assessment in a 71-year-old man.Acta myologica : myopathies and cardiomyopathies : official journal of the Mediterranean Society of Myology · 2024
    Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Shuai ShaoDepartment of Neurology, Xiangya Hospital, Central South University, Changsha, Hunan Province, China Xiangya.
Guanzhong ShiDepartment of Neurology, Xiangya Hospital, Central South University, Changsha, Hunan Province, China Xiangya.
Fang-Fang BiDepartment of Neurology, Xiangya Hospital, Central South University, Changsha, Hunan Province, China.
Kun HuangDepartment of Neurology, Xiangya Hospital, Central South University, Changsha, Hunan Province, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCongenital myasthenic syndromes (CMS) refer to a series of inherited disorders caused by defects in various proteins. Mutation in the collagen-like tail subunit of asymmetric acetylcholinesterase (

objectiveIn this study, we reviewed related reports to determine the most appropriate pharmacological strategy for CMS caused by

resultsA total of 42 studies including 164 patients with CMS due to 72 different

conclusion(1) β-adrenergic agonist therapy is the first pharmacological strategy for treating CMS with

Indexed as

Myasthenic Syndromes, CongenitalAcetylcholinesteraseAdrenergic beta-AgonistsCollagenHumansMuscle ProteinsMutationAcetylcholinesteraseAdrenergic beta-AgonistsCollagenCOLQ protein, humanMuscle ProteinsAChEIsCMSCOLQCongenital myasthenic syndromemutationβ-adrenergic agonist

Identifiers

PMID36703579
PMCPMC10472815

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.